Navigation Links
Angiotech to Establish Separate Operating and Royalty Businesses
Date:7/7/2008

tatements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for the second half of 2008 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research, development, product and drug development and our plans and anticipated effects of the transaction described in this press release. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements.

Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: the inability to consummate the transaction described in this press release or that the transaction will not provide the anticipated benefits described in this press release; general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand manufacturing and commercializati
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 22, 2013 First patients dosed ... glycopyrronium bromide designed using Prosonix, particle engineering platform ... portfolio of inhaled Respiratory Medicines by Design , ... that will assess its effect on lung function and ... with moderate to severe chronic obstructive pulmonary disease (COPD). ...
(Date:5/21/2013)... , May 21, 2013  The Lindsley F. Kimball ... that it is a Grand Challenges Explorations winner, ... Foundation .  Dr. Sara Lustigman , Head ... global health and development research project, titled Innovative 3-D ...  These worms are needed to screen drugs to help eliminate ...
(Date:5/21/2013)... 21, 2013 Through science fairs, workshops, ... for lab equipment, 25 organizations will continue their work ... optics and photonics in daily life with the aid ... organizations, located in 10 countries, are the first of ... by SPIE, the international society for optics and ...
(Date:5/21/2013)... May 21, 2013 Alpha Source, ... , will be exhibiting for the 13th consecutive ... Medical Instrumentation (AAMI) 2013 Conference and Expo. The ... distribute, and manufacture healthcare technologies. This year’s event ... Beach, California. , The three-day event draws ...
Breaking Biology Technology:Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 2New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 3Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 2Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 3Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2
... GERMANTOWN, Maryland and DES PLAINES, Illinois, October 12, 2010, ... ... ... // Results are keyed by longUrl, so we need to grab the first one. for (var r ...
... WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS ... today announced that Gary P. Schroth, Ph.D., who helped ... gene expression at Illumina, Inc., has joined the company ... new position created to build on the company,s technology ...
... than 200 researchers in attendance at the seventh ... that facilitate data-driven research: the Microsoft Biology Foundation ... (Logo: http://photos.prnewswire.com/prnh/20000822/MSFTLOGO ) (Logo: ... bioscience now have access to the first version ...
Cached Biology Technology:QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 2QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 3QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 4QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 5QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 6QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 7QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 8QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 9QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV 10WaferGen Names Gary P. Schroth, Ph.D., as New SVP, Genomics Research and Applications 2WaferGen Names Gary P. Schroth, Ph.D., as New SVP, Genomics Research and Applications 3WaferGen Names Gary P. Schroth, Ph.D., as New SVP, Genomics Research and Applications 4WaferGen Names Gary P. Schroth, Ph.D., as New SVP, Genomics Research and Applications 5Microsoft Research Makes Microsoft Biology Foundation and MODISAzure-Based Environmental Service Available to Scientists and Researchers 2Microsoft Research Makes Microsoft Biology Foundation and MODISAzure-Based Environmental Service Available to Scientists and Researchers 3Microsoft Research Makes Microsoft Biology Foundation and MODISAzure-Based Environmental Service Available to Scientists and Researchers 4
(Date:5/21/2013)... University of Illinois at Chicago College of Medicine will study ... -- its main energy source -- and how changes in ... new $2 million, 4-year grant from the National Heart, Lung ... it uses fuel for energy. These changes may play a ... different in men and women, says E. Douglas Lewandowski, director ...
(Date:5/21/2013)... the past few decades, scientists have developed many devices ... metallic stents. While generally effective, each of these treatments ... A new study from MIT analyzes the potential usefulness ... angioplasty balloons and drug-releasing stents, but may pose fewer ... in the artery for only a brief period, during ...
(Date:5/21/2013)... ANDOVER, Mass. , May 21, 2013 ... that CX50 xMATRIX, the world,s first portable ultrasound with ... Intracardiac Echo (ICE) capability. The CX50 xMATRIX with available ... Paris at the EuroPCR, official ... (EAPCI), May 21-24. Since its launch in ...
Breaking Biology News(10 mins):Do men's and women's hearts burn fuel differently? 2Evaluating a new way to open clogged arteries 2Evaluating a new way to open clogged arteries 3Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2
... may be the latest recipe for success when it comes ... the recent popular attention to the distance that food travels ... Christopher L. Weber and H. Scott Matthews argue in an ... that it is dietary choice, not food miles, which most ...
... lizards use to grab their grub influences how they move, ... team led by doctoral student Eric McElroy tracked 18 different ... to understand how their foraging styles impact their biomechanics. The ... the April 1 edition of the Journal of Experimental Biology. ...
... of Arctic sea ice is increasingly vulnerable to summer ... the National Center for Atmospheric Research (NCAR) and Colorado ... to last summer,s record loss of Arctic ice, while ... to have had comparable impacts. The study, which ...
Cached Biology News:Carnegie Mellon studies how climate change impacts food production 2Lizard hunting styles impact ability to walk, run 2Arctic ice more vulnerable to sunny weather, new study shows 2Arctic ice more vulnerable to sunny weather, new study shows 3
... Rabbit polyclonal to MLF1 Interacting ... for all tested applications). ... corresponding to amino acids 73-83 of ... Entrez Gene ID: 359815 ...
... 25 H 27 N 2 NaO 7 S ... Dark burgundy metallic powder Identity: By IR epsilon ... cm): greater than or equal to 60 x ... or equal to 10.0% lambda max ...
... Quixell, manufactured by Stoelting, selects single ... control. In no time at all, a ... on the keypad...the cell is collected into ... individual wells of a microtiter plate. Quixells ...
... genome-wide microRNA expression profiling and built ... microfluidic on-chip synthesis platform. These microarrays ... comprehensive microRNA Expression Profiling Service. ... microRNA Microarray contains all known virus ...
Biology Products: